Commercialization expert Bill Roth outlines the critical need for "adaptive capacity," detailing how accelerating government regulation and massive patent cliffs are forcing a complete overhaul of commercial strategies across various markets.
Bill Roth’s résumé is impressive, and that’s not just because he writes for us.
The commercialization expert’s experience spans 35 years—starting with Cardinal Health—and since that time, he went on to found the Blue Fin Group in 2001, which he then sold to IntegriChain nearly four years ago.
Now being the general manager and managing partner of IntegriChain’s consulting business, along with an editorial advisory board member and columnist of Pharma Commerce’s “Commercialization Corner,” this year marks the sixth year he’s given the keynote for Informa’s Trade & Channel Strategies conference in Philadelphia.
He also speaks at other events, raising the question, how does he keep the content fresh?
“The way that I do it is—and I train everyone at Blue Fin this way—that speaking is an audience- centered sport. It doesn't matter what I'm here to say. It matters what you're what you came here to hear,” he shares. “And within that, I think that there's an obligation that we all have right now to the teams that are coming in.”
Having said that, Roth centered this morning’s keynote on “Navigating Disruption in the Pharmaceutical Channels,” a compilation of 100-plus hours of work and research. He began by posing a question: what is the single most important characteristic of long-term survival/thriving? It revolves around adaptive capacity:
Roth’s overarching agenda, which is somewhat simplified and shortened below, consisted of macros; what’s not changing; a regulatory overview; what’s changing; what might change; and how one can prepare to thrive. “It’s difficult to be a futurist because what I've come to realize is that people don't like what you say when it affects them in a negative way. I don't say things to make it a negative way. I just see this as the world that I see coming.”
Macros have changed, but are used to see the archetypes that are driving the most change.
Firstly, when it comes to regulation and policy form, he notes that the government is throwing everything at the pharma industry to make it change its behaviors, including, BBA MMA, the Inflation Reduction Act, MFP, 340B rebates, tariffs, WAC reductions, and direct-to-patient (DTP) just to name a few. Five types of payers have come to light, including commercial concierge, commercial (DTE), Medicare, Medicaid, and consumer as payer (DTP).
There are nine distinctly different business models under two benefit scenarios (pharmacy versus medical), spanning three different lifecycles of launch, inline, and mature. For every model that aims to protect its business, there is a counter to that—those who could destroy it.
From a regulatory perspective, change has been accelerating, especially since 2010 with the Patient Protection and Affordable Care Act. The year 2023 saw Part B/D inflation and vial wastage rebates, while 2024 saw the AMP cap removal and MFP negotiations. This year, there’s been a Part D redesign, couple with most-favored nation developments, while 2026 will be the MFP effective date and the start of the 340B Rebate Model Pilot.
On the same front, what’s not changing in terms of launch are the new products that have launched in oncology, immunology, and neurology (MS) at higher price points. Meanwhile, those orphan/rare/low pop specialty drug will continue to be highly configurable with tight commercialization plans; the number of drugs in this market has seen an exponential rise, from 40 in 1983 to over 800 as of earlier this year. CGTs will also remain unchanged.
Here’s where it gets even more fascinating: general medicine, specialty (MS and immunology), and vaccines are all anticipated to change.
For one, GenMed has $180 billion that is set to go off patent. Eight of the first 10 MFP drugs are classified under this type of drug. Six of the 10 MFP products have also announced WAC decreases, and over 60 DTP efforts are currently underway. As for specialty, $200 billion-$230 billion is set to go off patent, and the MS class already has four generics.
One possibility is the formation of a “Medical benefit bubble.” Many might know about the pharmacy benefit—high WAC, high rebate—but in the medical benefit world, Roth says, ASP is equal to WAC. This won’t be the case in 2028, as he projects that MFP is going to be directly affected by the ASP.
Reference
Roth B. Navigating Disruption in the Pharmaceutical Channel. December 9, 2025. Trade & Channel Strategies, Philadelphia.
